TY - JOUR
T1 - Transdiagnostic subgroups of cognitive impairment in early affective and psychotic illness
AU - PRONIA-consortium
AU - Wenzel, Julian
AU - Badde, Luzie
AU - Haas, Shalaila S
AU - Bonivento, Carolina
AU - Van Rheenen, Tamsyn E
AU - Antonucci, Linda A
AU - Ruef, Anne
AU - Penzel, Nora
AU - Rosen, Marlene
AU - Lichtenstein, Theresa
AU - Lalousis, Paris Alexandros
AU - Paolini, Marco
AU - Stainton, Alexandra
AU - Dannlowski, Udo
AU - Romer, Georg
AU - Brambilla, Paolo
AU - Wood, Stephen J
AU - Upthegrove, Rachel
AU - Borgwardt, Stefan
AU - Meisenzahl, Eva
AU - Salokangas, Raimo K R
AU - Pantelis, Christos
AU - Lencer, Rebekka
AU - Bertolino, Alessandro
AU - Kambeitz, Joseph
AU - Koutsouleris, Nikolaos
AU - Dwyer, Dominic B
AU - Kambeitz-Ilankovic, Lana
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2024/2
Y1 - 2024/2
N2 - Cognitively impaired and spared patient subgroups were identified in psychosis and depression, and in clinical high-risk for psychosis (CHR). Studies suggest differences in underlying brain structural and functional characteristics. It is unclear whether cognitive subgroups are transdiagnostic phenomena in early stages of psychotic and affective disorder which can be validated on the neural level. Patients with recent-onset psychosis (ROP; N = 140; female = 54), recent-onset depression (ROD; N = 130; female = 73), CHR (N = 128; female = 61) and healthy controls (HC; N = 270; female = 165) were recruited through the multi-site study PRONIA. The transdiagnostic sample and individual study groups were clustered into subgroups based on their performance in eight cognitive domains and characterized by gray matter volume (sMRI) and resting-state functional connectivity (rsFC) using support vector machine (SVM) classification. We identified an impaired subgroup (N
ROP = 79, N
ROD = 30, N
CHR = 37) showing cognitive impairment in executive functioning, working memory, processing speed and verbal learning (all p < 0.001). A spared subgroup (N
ROP = 61, N
ROD = 100, N
CHR = 91) performed comparable to HC. Single-disease subgroups indicated that cognitive impairment is stronger pronounced in impaired ROP compared to impaired ROD and CHR. Subgroups in ROP and ROD showed specific symptom- and functioning-patterns. rsFC showed superior accuracy compared to sMRI in differentiating transdiagnostic subgroups from HC (BAC
impaired = 58.5%; BAC
spared = 61.7%, both: p < 0.01). Cognitive findings were validated in the PRONIA replication sample (N = 409). Individual cognitive subgroups in ROP, ROD and CHR are more informative than transdiagnostic subgroups as they map onto individual cognitive impairment and specific functioning- and symptom-patterns which show limited overlap in sMRI and rsFC. CLINICAL TRIAL REGISTRY NAME: German Clinical Trials Register (DRKS). Clinical trial registry URL: https://www.drks.de/drks_web/ . Clinical trial registry number: DRKS00005042.
AB - Cognitively impaired and spared patient subgroups were identified in psychosis and depression, and in clinical high-risk for psychosis (CHR). Studies suggest differences in underlying brain structural and functional characteristics. It is unclear whether cognitive subgroups are transdiagnostic phenomena in early stages of psychotic and affective disorder which can be validated on the neural level. Patients with recent-onset psychosis (ROP; N = 140; female = 54), recent-onset depression (ROD; N = 130; female = 73), CHR (N = 128; female = 61) and healthy controls (HC; N = 270; female = 165) were recruited through the multi-site study PRONIA. The transdiagnostic sample and individual study groups were clustered into subgroups based on their performance in eight cognitive domains and characterized by gray matter volume (sMRI) and resting-state functional connectivity (rsFC) using support vector machine (SVM) classification. We identified an impaired subgroup (N
ROP = 79, N
ROD = 30, N
CHR = 37) showing cognitive impairment in executive functioning, working memory, processing speed and verbal learning (all p < 0.001). A spared subgroup (N
ROP = 61, N
ROD = 100, N
CHR = 91) performed comparable to HC. Single-disease subgroups indicated that cognitive impairment is stronger pronounced in impaired ROP compared to impaired ROD and CHR. Subgroups in ROP and ROD showed specific symptom- and functioning-patterns. rsFC showed superior accuracy compared to sMRI in differentiating transdiagnostic subgroups from HC (BAC
impaired = 58.5%; BAC
spared = 61.7%, both: p < 0.01). Cognitive findings were validated in the PRONIA replication sample (N = 409). Individual cognitive subgroups in ROP, ROD and CHR are more informative than transdiagnostic subgroups as they map onto individual cognitive impairment and specific functioning- and symptom-patterns which show limited overlap in sMRI and rsFC. CLINICAL TRIAL REGISTRY NAME: German Clinical Trials Register (DRKS). Clinical trial registry URL: https://www.drks.de/drks_web/ . Clinical trial registry number: DRKS00005042.
UR - http://www.scopus.com/inward/record.url?scp=85171837194&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/4e605499-25ad-346b-bc7c-3f781d6f08a3/
U2 - 10.1038/s41386-023-01729-7
DO - 10.1038/s41386-023-01729-7
M3 - Journal articles
C2 - 37737273
SN - 0893-133X
VL - 49
SP - 573
EP - 583
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 3
ER -